CV
CapsoVision·NASDAQ
--
--(--)
--
--(--)
CV fundamentals
CapsoVision (CV) released its earnings on Mar 26, 2026: revenue was 4.40M (YoY --), beat estimates; EPS was -0.12 (YoY --), beat estimates.
Revenue / YoY
4.40M
--
EPS / YoY
-0.12
--
Report date
Mar 26, 2026
CV Earnings Call Summary for Q4,2025
- Revenue Momentum: 15% YoY growth driven by CapsoCam Plus adoption, 21% new account expansion.
- AI Innovation: AI-assisted reading module submission to enhance diagnostic efficiency.
- Pipeline Progress:
- CapsoCam Colon Gen 2 on track for Q3 2026 FDA submission, targeting late 2027 launch.
- Pancreatic cancer study (60-90 patients) to establish non-invasive screening criteria.
- Financial Resilience: $14M capital raise supports R&D and commercial growth, with $10.1M cash post-Q4.
EPS
Actual | -2.02 | -0.17 | -0.12 |
Forecast | -0.11 | -0.124 | -0.145 |
Surprise | -1736.36% | -37.10% | +17.24% |
Revenue
Actual | 3.31M | 3.54M | 4.40M |
Forecast | 3.25M | 3.67M | 4.30M |
Surprise | +2.11% | -3.60% | +2.35% |
Earnings Call
You can ask Aime
What factors drove the changes in CapsoVision's revenue and profit?What is the revenue and EPS growth rate for CapsoVision year over year?What were the key takeaways from CapsoVision’s earnings call?What does CapsoVision do and what are its main business segments?What guidance did CapsoVision's management provide for the next earnings period?What is CapsoVision's latest dividend and current dividend yield?Did CapsoVision beat or miss consensus estimates last quarter?What is the market's earnings forecast for CapsoVision next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
